Arginine

Arginine

SCHEMBL150228

N=C(N)NCCCC(N)C(=O)O.NC(CC(=O)O)C(=O)O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACES1PR1S1PR4S1PR5

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.49
DDAH1 O94760 3/20 0.46
NOS2 P35228 6/20 0.44
NOS3 P29474 5/20 0.44
NOS1 P29475 5/20 0.44
GSR P00390 2/20 0.42
CYP1A2 P05177 3/20 0.41
CYP2C19 P33261 2/20 0.41
TSHR P16473 2/20 0.41
GLA P06280 1/20 0.41
NFKB1 P19838 1/20 0.41
APEX1 P27695 1/20 0.41
GRM8 O00222 1/20 0.40
GRM6 O15303 1/20 0.40
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIK1 P39086 1/20 0.40
GRM5 P41594 1/20 0.40
GRIA1 P42261 1/20 0.40
GRIA2 P42262 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL248897 1.00 OTC (0.49) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL27692295 1.00 OTC (0.49) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL150229 1.00 OTC (0.49) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL27530824 1.00 OTC (0.49) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL27190202 0.98 OTC (0.48) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL8047291 0.98 OTC (0.48) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL8047296 0.98 OTC (0.48) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL8040299 0.97 OTC (0.47) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL8040301 0.97 OTC (0.47) OTCDDAH1NOS2NOS3NOS1
Arginine SCHEMBL4203993 0.95 OTC (0.46) OTCDDAH1NOS2NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1806 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115155-A1 STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN CHORDA PHARMA INC (US) 2026-04-30 US claimed
WO-2025124086-A1 MICROCARRIER, PREPARATION METHOD THEREFOR AND USE THEREOF, AND METHOD FOR CELL ADHERENT CULTURE AND RECOVERY 国科温州研究院(温州生物材料与工程研究所) 2025-06-19 WO claimed
CN-114728064-B Antibody-containing formulations 中外制药株式会社 2025-05-06 CN claimed
WO-2025077844-A1 A BIODEGRADABLE FLEXIBLE PACKAGE WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2025-04-17 WO claimed
WO-2025077840-A1 SQUEEZABLE FIBER-BASED BOTTLE WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2025-04-17 WO claimed
WO-2025076736-A1 SQUEEZABLE FIBER-BASED BOTTLE WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2025-04-17 WO claimed
WO-2025076732-A1 A BIODEGRADABLE FLEXIBLE PACKAGE WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2025-04-17 WO claimed
US-20250122672-A1 BIODEGRADABLE CONTAINER WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY 2025-04-17 US claimed
WO-2025080905-A1 A BIODEGRADABLE CONTAINER WITH A PERSONAL CARE COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2025-04-17 WO claimed
US-20250073170-A1 HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIES AmMax Bio, Inc. 2025-03-06 US claimed
WO-1994016740-A1 THE USE OF NITRIC OXIDE-DELIVERING COMPOUNDS FOR THE TREATMENT OR PREVENTION OF ALCOHOLIC LIVER INJURY BRIGHAM AND WOMEN'S HOSPITAL (US) 1994-08-04 WO claimed
US-5227007-A PROCESS FOR PRODUCING CRYSTALS OF SALT OF ACIDIC AMINO ACID AND BASIC AMINO ACID KYOWA HAKKO KOGYO CO., LTD. (JP) 1993-07-13 US claimed
EP-0342139-B1 USE OF ARGININE ASPARTATE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING CERTAIN INFLICTIONS OF THE MEMORY CORTIAL S.A. (FR) 1993-03-31 EP claimed
EP-0502007-A4 METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE 1992-11-19 EP claimed
EP-0502007-A1 ARGININE NICOTINATE FOR REDUCING BLOOD CHOLESTEROL BARBUL, Adrian (US) 1992-09-09 EP claimed
EP-0477991-A1 Process for producing crystals of salt of acidic amino acid and basic amino acid KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-04-01 EP claimed
WO-1991007188-A1 METHOD FOR REDUCING BLOOD CHOLESTEROL USING ARGININE BARBUL ADRIAN (US) 1991-05-30 WO claimed
US-5019558-A Cognition activators MEDA PHARMA (FR) 1991-05-28 US claimed
US-4804674-A ENHANCING SPERM MOTILITY EUROCELTIQUE, S.A. (LU) 1989-02-14 US claimed
EP-0242980-A2 Vaginal pharmaceutical composition Euroceltique S.A. (LU) 1987-10-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122672-A1 BIODEGRADABLE CONTAINER WITH A PERSONAL CARE COMPOSITION CUTA, IDUA, USP36 OTC 608/4885DDAH1 1380/4885NOS2 1480/4885
US-20260115155-A1 STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN TRPV1, SPTLC3, FFAR3 OTC 255/4885DDAH1 4408/4885NOS2 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.